These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6424379)

  • 1. Hereditary dysfibrinogenemia characterized by slow fibrinopeptide release and competitive inhibition of thrombin.
    Laugen RH; Bithell TC
    Acta Haematol; 1984; 71(3):150-7. PubMed ID: 6424379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A.
    Matsuda M; Saeki E; Kasamatsu A; Nakamikawa C; Manabe S; Samejima Y
    Thromb Res; 1985 Feb; 37(3):379-90. PubMed ID: 3992527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
    Lane DA; Cuddigan B; VanRoss M; Kakkar VV
    Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen Milano. VI: A heterozygous dysfibrinogenemia (A alpha 16 Arg----His) with bleeding tendency.
    Bögli C; Cofrancesco E; Cortellaro M; Della Volpe A; Hofer A; Furlan M; Zanussi C
    Eur J Haematol; 1990 Jul; 45(1):26-30. PubMed ID: 2379562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinogen New Orleans: hereditary dysfibrinogenemia with an A alpha chain abnormality.
    Andes WA; Chavin SI; Beltran G; Stuckey WJ
    Thromb Res; 1982 Jan 1-15; 25(1-2):41-50. PubMed ID: 6801812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hereditary dysfibrinogenemia: fibrinogen Awaji.
    Matsuo T; Okuno S; Mukaida T; Ueshima S; Okada K; Matsuo O
    Haemostasis; 1987; 17(1-2):89-97. PubMed ID: 3596361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An abnormal fibrinogen with delayed fibrinopeptide A release.
    Lane DA; VanRoss M; Kakkar VV; Bottomley KJ; Dhir K; Holt LP; MacIver JE
    Br J Haematol; 1980 Sep; 46(1):89-98. PubMed ID: 7426452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fibrinogen Bern III: a further case of hereditary fibrinogen variants with substitution A alpha 16 Arg----Cys].
    Furlan M; Leupin L; Biasiutti FD; Lämmle B
    Schweiz Med Wochenschr; 1991 Jul; 121(29):1068-71. PubMed ID: 1891701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution.
    Borrell M; Vila L; Solá J; Coll I; Fontcuberta J
    Haemostasis; 1990; 20(1):1-7. PubMed ID: 2323678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization.
    Lundberg UG; Rodriguez S; Marchi R; Ruiz-Saez A; Arocha-Piñango CL
    Thromb Res; 1995 Apr; 78(2):95-106. PubMed ID: 7482436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen Barcelona I. Congenital dysfibrinogenemia characterized by defective release of fibrinopeptide A and fibrinogen degradation products.
    Vila V; Regañón E; Aznar J; Navarro G; Salas M
    Thromb Res; 1987 Mar; 45(5):437-49. PubMed ID: 2954261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release.
    Yan J; Luo M; Cheng P; Liao L; Deng X; Deng D; Lin F
    Int J Hematol; 2017 Apr; 105(4):506-514. PubMed ID: 27933517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen Sapporo: dysfibrinogenemia characterized by the replacement of A alpha arginine-16 by histidine resulting in the delayed release of fibrinopeptide A by thrombin.
    Asakura S; Terukina S; Yamazumi K; Matsuda M; Murayama H; Higuchi A; Musashi M; Sakurada K; Miyazaki T
    Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1094-104. PubMed ID: 2588959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis.
    Haverkate F; Koopman J; Kluft C; D'Angelo A; Cattaneo M; Mannucci PM
    Thromb Haemost; 1986 Feb; 55(1):131-5. PubMed ID: 3705000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen Seattle II: defective release of fibrinopeptide A in a slow clotting fibrinogen.
    Schreiber WE; Schmer G
    Thromb Res; 1985 Jan; 37(1):45-52. PubMed ID: 3983901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysfibrinogenemia and lupus anticoagulant in a patient with recurrent thrombosis.
    Al-Mondhiry H; Galanakis D
    J Lab Clin Med; 1987 Dec; 110(6):726-33. PubMed ID: 3119749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen Milano IV, another case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A alpha 16 Arg----His).
    Bögli C; Hofer A; Baudo F; Redaelli R; Furlan M
    Haemostasis; 1992; 22(1):7-11. PubMed ID: 1521828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new congenital abnormal fibrinogen Ise characterized by the replacement of B beta glycine-15 by cysteine.
    Yoshida N; Wada H; Morita K; Hirata H; Matsuda M; Yamazumi K; Asakura S; Shirakawa S
    Blood; 1991 May; 77(9):1958-63. PubMed ID: 2018836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen Seattle releases half the normal amount of fibrinopeptide B.
    Branson HE; Schmer G; Theodor I; Pirkle H
    Acta Haematol; 1983; 70(4):257-63. PubMed ID: 6414212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen Petoskey: identification of a new dysfibrinogenemia characterized by altered release of fibrinopeptide A.
    Higgins DL; Penner JA; Shafer JA
    Thromb Res; 1981 Sep; 23(6):491-504. PubMed ID: 6459662
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.